-
August 13, 2015
What Determines Whether a Melanoma Patient Will Respond to Checkpoint Blockade Drugs?
Emma Shtivelman, PhDOf all cancer types, melanoma is the most investigated in terms of its potential to be treated through immune system-based approaches. More immunotherapy drugs are approved for melanoma than for any other type of cancer, and more are in development. Recent additions to the immunotherapy arsenal are the ‘anti-PD-1’ immune checkpoint blockade drugs pembrolizumab (Keytruda) and nivolumab (Opdivo).